Key facts
- Antengene will present preclinical data on ATG-207 at EULAR 2026.
- ATG-207 is an alpha-CD3-TGF-beta bifunctional fusion protein.
Antengene Corporation Limited, a global biotech company, announced it will present the first preclinical data for its drug candidate ATG-207 at the EULAR 2026 congress. ATG-207 is described as an alpha-CD3-TGF-beta bifunctional fusion protein. The company is focused on discovering, developing, and commercializing innovative medicines.